开放期刊系统

肾性贫血治疗研究进展

陈嘉琪, 金英顺

摘要

肾性贫血作为慢性肾脏病常见并发症，增加了患心血管事件发生的潜在风险，极大程度上影响了患者的生存质量。导致肾性贫血的机制十分复杂，涵盖了红细胞生成素绝对或相对不足、铁缺乏及代谢障碍、甲状旁腺功能亢进等因素。通过外源性补充促红细胞生成素、纠正铁缺乏状态、必要时输血是肾性贫血的主要治疗手段，近年来临床中应用罗沙司他为肾性贫血患者带来了新的治疗选择，铁调素的深入研究也为今后肾性贫血治疗提供了新思路。

关键词

慢性肾脏病；肾性贫血；药物治疗

全文:

PDF

参考

[1]VERDALLES U，ABAD S，VEGA A，等. Factors Related to the Absence of Anemia in Hemodialysis Patients[J/OL]. Blood

Purification，2011，32（1）：69-74.

[2]MEYTES D，BOGIN E，MA A，等. Effect of parathyroid hormone on erythropoiesis.[J/OL]. Journal of Clinical Investigation，1981，

67（5）：1263-1269.

[3]OGAWA C，TSUCHIYA K，MAEDA K，等. Renal Anemia and Iron Metabolism[M/OL]//NITTA K. Contributions to Nephrology：

卷 195. S. Karger AG，2018：62-73[2024-06-29]. https：//karger.com/books/book/133/chapter/5070773.

[4]ASAI H，HIRATA J，WATANABE-AKANUMA M. Indoxyl glucuronide，a protein-bound uremic toxin，inhibits hypoxia-inducible

factor‒dependent erythropoietin expression through activation of aryl hydrocarbon receptor[J/OL]. Biochemical and Biophysical Research

Communications，2018，504（2）：538-544.

[5]HERAS-BENITO M. Renal anemia：current treatments and emerging molecules[J/OL]. Revista Clinica Espanola，2023，223（7）：433-439.

[6]ZHOU Q G，JIANG J P，WU S J，等. Current pattern of Chinese dialysis units：a cohort study in a representative sample of units[J].

Chinese Medical Journal，2012，125（19）：3434-3439.

[7]CASES A，EGOCHEAGA M I，TRANCHE S，等. Anemia en la enfermedad renal crónica：protocolo de estudio，manejo y derivaci

ón a Nefrología[J/OL]. Atención Primaria，2018，50（1）：60-64.

[8]SMITH R E. The clinical and economic burden of anemia[J]. The American Journal of Managed Care，2010，16 Suppl Issues：S59-66.

[9]SAKASHITA M，TANAKA T，NANGAKU M. Hypoxia-Inducible Factor-Prolyl Hydroxylase Domain Inhibitors to Treat Anemia inChronic Kidney Disease[M/OL]//NAKANISHI T，KURAGANO T. Contributions to Nephrology：卷 198.S.KargerAG，2019：

112-123[2024-06-29]. https：//karger.com/books/book/125/chapter/5063994.

[10]YUGAVATHY N，ABDULLAH B M，LIM S K，等. Precision Medicine in Erythropoietin Deficiency and Treatment Resistance：A Novel

Approach to Management of Anaemia in Chronic Kidney Disease[J/OL]. Current Issues in Molecular Biology，2023，45（8）：6550-6563.

[11]KIDANEWOLD A，WOLDU B，ENAWGAW B. Role of Erythropoiesis Stimulating Agents in the Treatment of Anemia：a Literature

Review[J/OL]. Clinical Laboratory，2021，67（04/2021）[2024-06-29]. http：//www.clin-lab-publications.com/article/3735.

[12]中国医师协会肾脏内科医师分会肾性贫血指南工作组.中国肾性贫血诊治临床实践指南[J]. 中华医学杂志，2021，101（20）：1463-1502.

[13]SAGLIMBENE V M，PALMER S C，RUOSPO M，等. Continuous erythropoiesis receptor activator（CERA）for the anaemia of chronic

kidney disease[J/OL]. The Cochrane Database of Systematic Reviews，2017，8（8）：CD009904.

[14]CORWIN H L，GETTINGER A，FABIAN T C，等. Efficacy and safety of epoetin alfa in critically ill patients[J/OL]. The New

England Journal of Medicine，2007，357（10）：965-976.

[15]KAHN T，BOSCH J，LEVITT M F，等. Effect of sodium nitrate loading on electrolyte transport by the renal tubule[J/OL]. The

American Journal of Physiology，1975，229（3）：746-753.

[16]MACDOUGALL I C，ROGER S D，DE FRANCISCO A，等. Antibody-mediated pure red cell aplasia in chronic kidney disease

patients receiving erythropoiesis-stimulating agents：new insights[J/OL]. Kidney International，2012，81（8）：727-732.

[17]COURNOYER D，TOFFELMIRE E B，WELLS G A，等. Anti-Erythropoietin Antibody-Mediated Pure Red Cell Aplasia after

Treatment with Recombinant Erythropoietin Products：Recommendations for Minimization of Risk[J/OL]. Journal of the American Society

of Nephrology，2004，15（10）：2728-2734.

[18]WISH J B. Assessing Iron Status：Beyond Serum Ferritin and Transferrin Saturation[J/OL]. Clinical Journal of the American Society

of Nephrology，2006，1（Supplement_1）：S4-S8.

[19]BAZELEY J W，WISH J B. Recent and Emerging Therapies for Iron Deficiency in Anemia of CKD：A Review[J/OL]. American

Journal of Kidney Diseases，2022，79（6）：868-876.

[20]BONOMINI M，DEL VECCHIO L，SIROLLI V，等. New Treatment Approaches for the Anemia of CKD[J/OL]. American Journal of

Kidney Diseases，2016，67（1）：133-142.

[21]YAN L，COLANDREA V J，HALE J J. Prolyl hydroxylase domain-containing protein inhibitors as stabilizers of hypoxia-inducible

factor：small molecule-based therapeutics for anemia[J/OL]. Expert Opinion on Therapeutic Patents，2010，20（9）：1219-1245.

[22]PROVENZANO R，BESARAB A，WRIGHT S，等. Roxadustat（FG-4592）Versus Epoetin Alfa for Anemia in Patients Receiving

Maintenance Hemodialysis：A Phase 2，Randomized，6- to 19-Week，Open-Label，Active-Comparator，Dose-Ranging，Safety and

Exploratory Efficacy Study[J/OL]. American Journal of Kidney Diseases，2016，67（6）：912-924.

[23]VAZIRI N D，ZHOU X J. Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic

kidney disease[J/OL]. Nephrology，Dialysis，Transplantation：Official Publication of the European Dialysis and Transplant Association

- European Renal Association，2009，24（4）：1082-1088.

[24]HAASE V H. Regulation of erythropoiesis by hypoxia-inducible factors[J/OL]. Blood Reviews，2013，27（1）：41-53.

[25]TAYLOR C T，SCHOLZ C C. The effect of HIF on metabolism and immunity[J/OL]. Nature Reviews Nephrology，2022，18（9）：573-587.

[26]SANGHANI N S，HAASE V H. Hypoxia-Inducible Factor Activators in Renal Anemia：Current Clinical Experience[J/OL].

Advances in Chronic Kidney Disease，2019，26（4）：253-266.

[27]GROENENDAAL-VAN DE MEENT D，DEN ADEL M，VAN DIJK J，等. Effect of Multiple Doses of Omeprazole on the

Pharmacokinetics，Safety，and Tolerability of Roxadustat in Healthy Subjects[J/OL]. European Journal of Drug Metabolism and

Pharmacokinetics，2018，43（6）：685-692.

[28]AGARWAL A K，YEE J. Hepcidin[J/OL]. Advances in Chronic Kidney Disease，2019，26（4）：298-305.

[29]SANGKHAE V，NEMETH E. Regulation of the Iron Homeostatic Hormone Hepcidin[J/OL]. Advances in Nutrition，2017，8（1）：126-136.

[30]RISHI G，SUBRAMANIAM V N. Signaling pathways regulating hepcidin[M/OL]//Vitamins and Hormones：卷 110. Elsevier，2019：

47-70[2024-06-30]. https：//linkinghub.elsevier.com/retrieve/pii/S0083672919300032.

[31]LI J，NEAL B，PERKOVIC V，等. Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes[J/OL].

Kidney International，2020，98（3）：769-777.

[32]ZHONG H，LIN W，ZHOU T. Current and Emerging Drugs in the Treatment of Anemia in Patients with Chronic Kidney

Disease[J/OL]. Journal of Pharmacy & Pharmaceutical Sciences，2020，23：278-288.

[33]ZHU Y，TANG Y，HE H，等. Gut Microbiota Correlates With Clinical Responsiveness to Erythropoietin in Hemodialysis Patients

With Anemia[J/OL]. Frontiers in Cellular and Infection Microbiology，2022，12：919352.

(29 摘要 Views, 458 PDF Downloads)

Refbacks

当前没有refback。

用户名
密码
记住我